BAGLIVO, SARA
 Distribuzione geografica
Continente #
NA - Nord America 946
AS - Asia 794
EU - Europa 560
SA - Sud America 159
AF - Africa 27
OC - Oceania 2
Totale 2.488
Nazione #
US - Stati Uniti d'America 913
SG - Singapore 382
CN - Cina 129
BR - Brasile 125
IE - Irlanda 109
IT - Italia 103
HK - Hong Kong 86
RU - Federazione Russa 78
DE - Germania 77
VN - Vietnam 58
FR - Francia 47
RO - Romania 27
KR - Corea 26
FI - Finlandia 24
BD - Bangladesh 23
IN - India 23
GB - Regno Unito 20
AR - Argentina 14
CA - Canada 14
JP - Giappone 13
PL - Polonia 12
AT - Austria 11
ES - Italia 11
MX - Messico 11
MA - Marocco 10
SE - Svezia 10
IQ - Iraq 9
NL - Olanda 8
TR - Turchia 7
ZA - Sudafrica 7
PK - Pakistan 6
VE - Venezuela 6
CH - Svizzera 5
JO - Giordania 5
EC - Ecuador 4
EG - Egitto 4
PY - Paraguay 4
SA - Arabia Saudita 4
UZ - Uzbekistan 4
GR - Grecia 3
TT - Trinidad e Tobago 3
UA - Ucraina 3
AE - Emirati Arabi Uniti 2
AZ - Azerbaigian 2
BO - Bolivia 2
CO - Colombia 2
DZ - Algeria 2
ID - Indonesia 2
JM - Giamaica 2
LB - Libano 2
LT - Lituania 2
OM - Oman 2
PH - Filippine 2
BA - Bosnia-Erzegovina 1
BE - Belgio 1
BG - Bulgaria 1
BH - Bahrain 1
CL - Cile 1
DO - Repubblica Dominicana 1
GA - Gabon 1
HN - Honduras 1
HU - Ungheria 1
IR - Iran 1
KI - Kiribati 1
LV - Lettonia 1
ME - Montenegro 1
MN - Mongolia 1
MT - Malta 1
MY - Malesia 1
NG - Nigeria 1
NP - Nepal 1
PE - Perù 1
PS - Palestinian Territory 1
PT - Portogallo 1
PW - Palau 1
RS - Serbia 1
SI - Slovenia 1
SO - Somalia 1
SV - El Salvador 1
TN - Tunisia 1
TW - Taiwan 1
Totale 2.488
Città #
Singapore 293
Chandler 145
San Jose 121
Dublin 109
Hong Kong 85
Ashburn 67
Beijing 38
San Mateo 35
Santa Clara 35
Boardman 34
Munich 33
Perugia 32
Bucharest 27
Seoul 26
Moscow 25
Los Angeles 24
Lauterbourg 22
Altamura 21
Lawrence 20
Medford 20
Princeton 20
Ho Chi Minh City 19
New York 16
Ann Arbor 14
Frankfurt am Main 14
Helsinki 14
Tokyo 13
Warsaw 12
Andover 11
São Paulo 11
Wilmington 11
Piscataway 10
Des Moines 9
Hanoi 9
Falkenstein 8
Nuremberg 8
Stockholm 8
The Dalles 8
Mexico City 7
Orem 7
Baghdad 6
Hefei 6
San Paolo di Civitate 6
Seattle 6
Atlanta 5
Brasília 5
Chennai 5
Haiphong 5
Houston 5
Johannesburg 5
Montreal 5
Phoenix 5
Redmond 5
Rio de Janeiro 5
Turku 5
Vienna 5
Amman 4
Arezzo 4
Brooklyn 4
Curitiba 4
Dearborn 4
Denver 4
Guangzhou 4
Lahore 4
Nanjing 4
Paris 4
Rome 4
Saint Petersburg 4
San Francisco 4
Amsterdam 3
Ankara 3
Bexley 3
Calgary 3
Chicago 3
Council Bluffs 3
Formia 3
Hải Dương 3
Mumbai 3
Poplar 3
Rabat 3
Tianjin 3
Toronto 3
Anápolis 2
Boston 2
Cairo 2
Caracas 2
City of London 2
Columbus 2
Dallas 2
Erbil 2
Faenza 2
Foligno 2
Ghaziabad 2
Governador Valadares 2
Guayaquil 2
Lappeenranta 2
Londrina 2
Manchester 2
New Delhi 2
Norfolk 2
Totale 1.652
Nome #
Prognostic Role of Circulating miRNAs in Early-Stage Non-Small Cell Lung Cancer 128
Identification of EML4-ALK Rearrangement and MET Exon 14 R988C Mutation in a Patient with High-Grade Neuroendocrine Lung Carcinoma Who Experienced a Lazarus Response to Crizotinib 120
Targeting indoleamine-2,3-dioxygenase in cancer: Scientific rationale and clinical evidence 113
Large Cell Neuroendocrine Carcinoma Transformation and EGFR-T790M Mutation as Coexisting Mechanisms of Acquired Resistance to EGFR-TKIs in Lung Cancer 108
Higher tlr7 gene expression predicts poor clinical outcome in advanced nsclc patients treated with immunotherapy 108
Non-coding RNAs in lung cancer 104
Osimertinib 98
Precision medicine against ALK-positive non-small cell lung cancer: beyond crizotinib 98
Reverse phase protein array (RPPA) combined with computational analysis to unravel relevant prognostic factors in non- small cell lung cancer (NSCLC): a pilot study 96
Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: rationale, evidence and place in therapy 96
High PD-L1/IDO-2 and PD-L2/IDO-1 Co-Expression Levels Are Associated with Worse Overall Survival in Resected Non-Small Cell Lung Cancer Patients 96
Targeting the KRAS variant for treatment of non-small cell lung cancer: Potential therapeutic applications 92
Long-term survival with erlotinib in advanced lung adenocarcinoma harboring synchronous EGFR G719S and KRAS G12C mutations 90
KRAS mutation and DNA repair and synthesis genes in non-small-cell lung cancer 89
MiRNAs and resistance to EGFRâ€"TKIs in EGFR-mutant non-small cell lung cancer: Beyond 'traditional mechanisms' of resistance 84
Dynamic network topologies analysis in proteomics data of NSCLC cell lines using a new pipeline based on machine learning tools 83
Sensitivity to immune checkpoint blockade in advanced non-small cell lung cancer patients with EGFR exon 20 insertion mutations 82
Extracellular vesicles miR-574-5p and miR-181a-5p as prognostic markers in NSCLC patients treated with nivolumab 80
Lorlatinib beyond progression plus platinum/pemetrexed for ALK-positive non-small cell lung cancer patients: report of two cases 76
Clinical outcomes to pemetrexed-based versus non-pemetrexed-based platinum doublets in patients with KRAS-mutant advanced non-squamous non-small cell lung cancer 76
Detection of egfr mutations in plasma cell-free tumor dna of tki-treated advanced-nsclc patients by three methodologies: Scorpion-arms, pnaclamp, and digital pcr 75
Repotrectinib’s Clinical Benefit and Its Brain Penetration in a Patient with Meningeal Carcinomatosis from G2032R-Mutated ROS-1 Positive Non-Small Cell Lung Cancer 73
Targeting NTRK fusion in non-small cell lung cancer: rationale and clinical evidence 72
Successful Response to Osimertinib Rechallenge after Intervening Chemotherapy in an EGFR T790M-Positive Lung Cancer Patient. 70
Correction: Repotrectinib’s Clinical Benefit and Its Brain Penetration in a Patient with Meningeal Carcinomatosis from G2032R-Mutated ROS-1 Positive Non-Small Cell Lung Cancer (Oncology and Therapy, (2024), 12, 1, (163-171), 10.1007/s40487-023-00251-6) 68
Prognosis of ALK-rearranged non-small-cell lung cancer patients carrying TP53 mutations 67
Concomitant TP53 Mutation Confers Worse Prognosis in EGFR-Mutated Non-Small Cell Lung Cancer Patients Treated with TKIs 63
RET Rearrangement as a Predictor of Unresponsiveness to Immunotherapy in Non-Small Cell Lung Cancer: Report of Two Cases with Review of the Literature 62
Is There a Role for Multiple Lines of Anti-HER2 Therapies Administered Beyond Progression in HER2-Mutated Non-Small Cell Lung Cancer? A Case Report and Literature Review 55
Safety and Efficacy of Nivolumab in Patients With Advanced Non-small-cell Lung Cancer Treated Beyond Progression 48
Totale 2.570
Categoria #
all - tutte 11.544
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 11.544


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022170 1 25 1 5 4 3 1 47 2 22 24 35
2022/2023398 22 75 9 37 38 40 0 18 142 0 14 3
2023/2024158 8 10 16 6 2 2 39 1 4 5 36 29
2024/2025418 10 31 31 12 46 33 9 32 70 34 67 43
2025/20261.249 65 97 72 185 198 93 189 69 118 115 36 12
Totale 2.570